Cognition Therapeutics completes Type C meeting with FDA for zervimesine

Cognition Therapeutics (CGTX) conducted a Type C meeting with the U.S. Food and Drug Administration on January 21, 2026. The objective of this meeting was to review plans for the proposed Phase 2b study of zervimesine in dementia with Lewy bodies, a disease with no FDA-approved therapies. “We had a productive meeting with the FDA, during which we discussed clinically meaningful endpoints for the next Phase 2b study of mild-to-moderate DLB,” stated Anthony O. Caggiano, MD, PhD, Cognition’s chief medical officer. “We look forward to receiving meeting minutes later this quarter and continuing our dialogue with the FDA to advance clinical development in DLB.”